Trial reportJournal of geriatric oncology2022
Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.
Trial report in Journal of geriatric oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03226418 (A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.American journal of hematology · 2025Trial
- Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia.Journal of geriatric oncology · 2024Trial
- Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statement.Internal medicine journal · 2025Article
- Developing a National Study That Integrates the Geriatric Assessment into the Care of Older Patients with Myeloid Malignancies.Current oncology reports · 2024Review
- Evaluating Fitness in Older Acute Myeloid Leukemia Patients: Balancing Therapy and Treatment Risks.Journal of clinical medicine · 2024Review
- Article
- Geriatric Assessment in Acute Myeloid Leukemia.Acta haematologica · 2024Review
- The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia.JCO oncology practice · 2023Review
- How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.Current treatment options in oncology · 2022Review
- Challenges in Geriatric Oncology-A Surgeon's Perspective.Current oncology (Toronto, Ont.) · 2022Review
- Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future.Journal of geriatric oncology · 2021Article
- A precision medicine approach to management of acute myeloid leukemia in older adults.Current opinion in oncology · 2020Review
- Novel Treatment Paradigms in Acute Myeloid Leukemia.Clinical pharmacology and therapeutics · 2020Review
- Geriatric hematology research at the 2019 American Society of Hematology annual meeting: Young International Society of geriatric oncology perspective paper.Journal of geriatric oncology · 2020Article
- Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.Clinical lymphoma, myeloma & leukemia · 2020Article
- Geriatric assessment for the practicing clinician: The why, what, and how.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
introductionSurvival benefit associated with intensive over low-intensity chemotherapy in older adults with acute myeloid leukemia (AML) is controversial. Geriatric assessment and genetic risk categories correlate with survival following intensive chemotherapy in older adults with AML and can guide treatment selection. MATERIALS AND
methodsIn a single-center trial, we integrated both geriatric assessment, and genetic risk categories to personalize selection of intensive versus low-intensity chemotherapy in older adults ≥60 years with AML (NCT03226418). In the present report, we demonstrate feasibility of this approach.
resultsBroad eligibility criteria and co-management of patients with community oncologists allowed enrollment of 45% of all patients with AML treated at our center during the study period. The median time from enrollment to therapy initiation was two days (range 0-9). Over half of the trial patients had a score of ≥3 on hematopoietic cell transplantation comorbidity index, impairment in physical function (Short Physical Performance Battery), and Montreal Cognitive Assessment. Three fit patients received intensive chemotherapy, whereas other patients received low-intensity chemotherapy. Mortality at 30 days from diagnosis was 3.7% (95% confidence interval [CI] 0.7-18.3%) and at 90 days was 29.6% (95% CI 15.9-48.5%). One-year overall survival was 66% (95% CI 60-87%). DISCUSSION: Our data demonstrate the feasibility of integrating geriatric assessment in precision oncology trials to define fitness for intensive chemotherapy. Broad eligibility criteria and academic-community collaboration can expand access to clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.